In March 2025, the company declared new programs for just a direct-to-client providing of its Wegovy weight loss drug. The company recognized a new pharmacy, identified as NovoCare, which might charge customers $499 each month for access to the drug, under 50 percent the expense of the drug through other pharmaceutical distribution networks.[fifty